

CURRENT STATUS OF CLAIMS WITH CLAIM AMENDMENTS

1-7. **Canceled.**

8. **(Presently amended)** [The method of claim 1, wherein said VEGFR-3 inhibitor is a VEGFR-3] **A method of extending corneal graft survival following corneal transplantation in a patient, comprising:**

administering to said patient an effective amount of a pharmaceutical composition comprising a vascular endothelial growth factor receptor-3 (VEGFR-3) kinase inhibitor,

whereby lymphangiogenesis is suppressed in the cornea of said patient.

9. **(Original)** The method of claim 8, wherein said VEGFR-3 kinase inhibitor binds the VEGFR-3 catalytic domain.

10. **(Original)** The method of claim 9, wherein said VEGFR-3 kinase inhibitor is an ATP analog.

11-14. **Canceled.**

15. **(Presently amended)** The method of claim 8 [1], wherein said VEGFR-3 inhibitor down-regulates VEGFR-3 expression.

16-25. **Canceled.**

26. **(Presently amended)** The method of claim 8 [1], further comprising administering to said patient an anti-angiogenic agent.

27. **(Presently amended)** The method of claim 8 [1] or claim 26, further comprising administering to said patient an immunosuppressive agent.

28. **(Presently amended)** The method of claim 8 [1], wherein said pharmaceutical composition is administered prior to corneal transplantation.

29. **(Presently amended)** The method of claim 8 [1], wherein said pharmaceutical composition is administered subsequent to corneal transplantation.

30. **(Presently amended)** The method of claim 8 [1], comprising administering to said patient an effective amount of a pharmaceutical composition comprising a VEGFR-3 inhibitor two or more times.

31. (Original) The method of claim 30, comprising repeated administration over a period of at least one month.

32. (Original) The method of claim 30, comprising repeated administration over a period of at least six months.

33. (Original) The method of claim 30, comprising:

(a) administering to said patient prior to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 inhibitor; and

(b) administering to said patient subsequent to corneal transplantation a pharmaceutical composition comprising a VEGFR-3 inhibitor,

whereby lymphangiogenesis is suppressed in the cornea of said patient.

34. **(Presently amended)** The method of claim 8 [1], comprising systemic administration of said pharmaceutical composition.

35. **(Presently amended)** The method of claim 8 [1], comprising local administration of said pharmaceutical composition.

36. (Original) The method of claim 35, comprising topical administration of said pharmaceutical composition.

37. (Original) The method of claim 35, comprising local injection of said pharmaceutical composition.

38. (Original) The method of claim 35, said pharmaceutical composition released from an intraocular or periocular implant.